Pulmonary Vein News and Research

RSS

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

Medtronic's anatomically-designed ablation catheters reduce lab time for PVI

Data from the FAST-PVI study, supported by Medtronic, Inc., shows lab time using anatomically-designed ablation catheters are more than one-third (35 percent) faster than traditional point-by-point focal ablation procedures in achieving pulmonary vein isolation (PVI). PVI is the cornerstone catheter procedure to treat paroxysmal atrial fibrillation (PAF).

19 Jun 2010

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced it has enrolled the first patients in EFFICAS I, the first study of the EFFICAS series. These patients were enrolled in Na Homolce Hospital, Prague, Czech Republic and treated by Petr Neuzil, M.D. and Vivek Reddy, M.D.

10 May 2010

Biosense Webster obtains first Ethics Committee approval for CLARITY study

Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Apr 2010

St. Jude Medical to commence enrollment in IRASE AF trial

St. Jude Medical, Inc. today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the IRASE AF (IRrigated Ablation System Evaluation for AF) trial, a multicenter, randomized, single-blind study evaluating the safety and efficacy of the company’s Duo 12 port open irrigated catheter ablation system for treatment of Atrial Fibrillation (AF). AF is the most common cardiac arrhythmia (abnormal heartbeat), affecting an estimated 3.3 million Americans and millions more worldwide.

4 Feb 2010

AFib: NAVISTAR THERMOCOOL Catheter provides better outcomes compared to drug therapy

According to data appearing today in JAMA, patients with a common heart rhythm disorder, called Atrial Fibrillation, who were treated with catheter ablation using the NAVISTAR® THERMOCOOL® Catheter, demonstrated significantly better outcomes at one year compared to those receiving drug therapy. In addition, the patients treated with catheter ablation reported markedly fewer symptoms and substantially improved quality of life.

27 Jan 2010

nContact Surgical initiates clinical trials of its convergent procedure for paroxysmal AF

nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, today announced the initiation of a feasibility clinical trial designed to evaluate the safety and efficacy of a combined surgical and catheter procedure, the convergent procedure, for the treatment of symptomatic paroxysmal atrial fibrillation (AF). This prospective, feasibility study will enroll patients at study sites across the United States.

2 Dec 2009

Positive short term results from combined surgical and electrophysiological approach to treat AF

nContact Surgical, Inc., a leader in the investigation of devices for minimally-invasive treatment for heart conditions, announced that data from a poster was presented at the American Heart Association Scientific Sessions in Orlando. The study demonstrated that the convergent approach, which combines surgical and electrophysiological expertise, appears to be a good strategy to achieve short term success in patients with long standing persistent atrial fibrillation (AF).

20 Nov 2009

FDA clears Hansen Medical's Sensei X Robotic Catheter System

Furthering the medical robotic frontier in electrophysiology (EP), Hansen Medical, Inc. (NASDAQ: HNSN) today announced it has received U.S. Food & Drug Administration (FDA) clearance for its next generation Sensei® X Robotic Catheter System and it introduced the Artisan Extend™ Control Catheter. The company also introduced the Lynx™ Robotic Ablation Catheter, a small, flexible irrigated ablation catheter for customers in Europe.

16 Sep 2009

FDA approves first ablation catheters for the treatment of atrial fibrillatio

The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms--affecting more than two million Americans.

8 Feb 2009

Robotic navigation systems in electrophysiology

Catheter ablation is still associated with a substantial amount of complications, and more failure then sometimes reported. Perforation with catheters is especially important in atrial fibrillation. Robotic navigation could reduce these complications.

1 Sep 2008

First mouse model of lung transplantation

Lung transplants have been performed successfully for more than 20 years in humans but never before in mice – until now.

12 Jul 2007

Catheter ablation for chronic atrial fibrillation improves quality of life

People who have endured the effects and risks of an irregular heartbeat for years can get long-lasting relief from a procedure that takes less than two hours, a definitive new study shows.

7 Mar 2006

High-tech imaging software locates more accurately the abnormal electrical impulses that produce heart arrhythmias

Loyola University Health System is one of the first hospitals in the United States to employ new high-tech imaging software - in conjunction with a three-dimensional cardiac mapping and navigation system - to locate more accurately the abnormal electrical impulses that produce heart rhythm disturbances (arrhythmias). This technology represents a major breakthrough in treating complex arrhythmias.

3 Jun 2005